Cargando…
How the COVID-19 pandemic changed treatment of severe aortic stenosis: a single cardiac center experience
BACKGROUND: Currently, two effective therapeutic options for severe aortic stenosis (AS) are available, one catheter-based [transcatheter aortic valve implantation (TAVI)], the other open surgical approach [surgical aortic valve replacement (SAVR)]. The COVID-19 pandemic has limited the availability...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947507/ https://www.ncbi.nlm.nih.gov/pubmed/33717563 http://dx.doi.org/10.21037/jtd-20-3025 |
_version_ | 1783663243769675776 |
---|---|
author | Perek, Bartlomiej Olasinska-Wisniewska, Anna Misterski, Marcin Puslecki, Mateusz Grygier, Marek Buczkowski, Piotr Lesiak, Maciej Stankowski, Tomasz Szarpak, Lukasz Ruetzler, Kurt Turan, Oguz Jemielity, Marek |
author_facet | Perek, Bartlomiej Olasinska-Wisniewska, Anna Misterski, Marcin Puslecki, Mateusz Grygier, Marek Buczkowski, Piotr Lesiak, Maciej Stankowski, Tomasz Szarpak, Lukasz Ruetzler, Kurt Turan, Oguz Jemielity, Marek |
author_sort | Perek, Bartlomiej |
collection | PubMed |
description | BACKGROUND: Currently, two effective therapeutic options for severe aortic stenosis (AS) are available, one catheter-based [transcatheter aortic valve implantation (TAVI)], the other open surgical approach [surgical aortic valve replacement (SAVR)]. The COVID-19 pandemic has limited the availability of medical procedures. The purpose of this cross-sectional study was to assess if this pandemic had any impact on the treatment strategy of severe AS in a single cardiac center. METHODS: This study involved AS patients treated in 3-month periods (February through April) over 3 consecutive years 2018, 2019 [defined as COV(–) group] and 2020 [COV(+)]. We assessed if there were any differences regarding patients’ clinical profile, applied therapeutic method, procedure complexity and early clinical outcomes. RESULTS: In the years 2018 through 2019, approximately 50% of AS patients were treated classically (SAVR) while in 2020 this rate dropped to 34%. The preoperative clinical characteristic of TAVI subjects was comparable irrespective of the year. Regarding SAVR, more patients in COV(+) underwent urgent and more complex procedures. More of them were found in NYHA class III or IV, and had lower left ventricular ejection fraction (LVEF) (51.9%±14.4% vs. 58.3%±8.1%; P=0.021) than in COV(–) individuals. During the pandemic, a change in applied therapeutic methods and differences in patients’ clinical profile did not have an unfavorable impact on in-hospital mortality (2.0% before vs. 3.6% during pandemic) and morbidity. Of note, intubation time and in-hospital stay were significantly shorter (P<0.05) in 2020 (4.2 hours and 7.5 days) than in the previous years (7.5 hours and 9.0 days, respectively). CONCLUSIONS: The coronavirus pandemic has changed substantially the management of severe AS. The shift into less invasive treatment method of AS patients resulted in shortening of in-hospital stay without compromise of short-term outcomes. |
format | Online Article Text |
id | pubmed-7947507 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-79475072021-03-12 How the COVID-19 pandemic changed treatment of severe aortic stenosis: a single cardiac center experience Perek, Bartlomiej Olasinska-Wisniewska, Anna Misterski, Marcin Puslecki, Mateusz Grygier, Marek Buczkowski, Piotr Lesiak, Maciej Stankowski, Tomasz Szarpak, Lukasz Ruetzler, Kurt Turan, Oguz Jemielity, Marek J Thorac Dis Original Article BACKGROUND: Currently, two effective therapeutic options for severe aortic stenosis (AS) are available, one catheter-based [transcatheter aortic valve implantation (TAVI)], the other open surgical approach [surgical aortic valve replacement (SAVR)]. The COVID-19 pandemic has limited the availability of medical procedures. The purpose of this cross-sectional study was to assess if this pandemic had any impact on the treatment strategy of severe AS in a single cardiac center. METHODS: This study involved AS patients treated in 3-month periods (February through April) over 3 consecutive years 2018, 2019 [defined as COV(–) group] and 2020 [COV(+)]. We assessed if there were any differences regarding patients’ clinical profile, applied therapeutic method, procedure complexity and early clinical outcomes. RESULTS: In the years 2018 through 2019, approximately 50% of AS patients were treated classically (SAVR) while in 2020 this rate dropped to 34%. The preoperative clinical characteristic of TAVI subjects was comparable irrespective of the year. Regarding SAVR, more patients in COV(+) underwent urgent and more complex procedures. More of them were found in NYHA class III or IV, and had lower left ventricular ejection fraction (LVEF) (51.9%±14.4% vs. 58.3%±8.1%; P=0.021) than in COV(–) individuals. During the pandemic, a change in applied therapeutic methods and differences in patients’ clinical profile did not have an unfavorable impact on in-hospital mortality (2.0% before vs. 3.6% during pandemic) and morbidity. Of note, intubation time and in-hospital stay were significantly shorter (P<0.05) in 2020 (4.2 hours and 7.5 days) than in the previous years (7.5 hours and 9.0 days, respectively). CONCLUSIONS: The coronavirus pandemic has changed substantially the management of severe AS. The shift into less invasive treatment method of AS patients resulted in shortening of in-hospital stay without compromise of short-term outcomes. AME Publishing Company 2021-02 /pmc/articles/PMC7947507/ /pubmed/33717563 http://dx.doi.org/10.21037/jtd-20-3025 Text en 2021 Journal of Thoracic Disease. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Original Article Perek, Bartlomiej Olasinska-Wisniewska, Anna Misterski, Marcin Puslecki, Mateusz Grygier, Marek Buczkowski, Piotr Lesiak, Maciej Stankowski, Tomasz Szarpak, Lukasz Ruetzler, Kurt Turan, Oguz Jemielity, Marek How the COVID-19 pandemic changed treatment of severe aortic stenosis: a single cardiac center experience |
title | How the COVID-19 pandemic changed treatment of severe aortic stenosis: a single cardiac center experience |
title_full | How the COVID-19 pandemic changed treatment of severe aortic stenosis: a single cardiac center experience |
title_fullStr | How the COVID-19 pandemic changed treatment of severe aortic stenosis: a single cardiac center experience |
title_full_unstemmed | How the COVID-19 pandemic changed treatment of severe aortic stenosis: a single cardiac center experience |
title_short | How the COVID-19 pandemic changed treatment of severe aortic stenosis: a single cardiac center experience |
title_sort | how the covid-19 pandemic changed treatment of severe aortic stenosis: a single cardiac center experience |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947507/ https://www.ncbi.nlm.nih.gov/pubmed/33717563 http://dx.doi.org/10.21037/jtd-20-3025 |
work_keys_str_mv | AT perekbartlomiej howthecovid19pandemicchangedtreatmentofsevereaorticstenosisasinglecardiaccenterexperience AT olasinskawisniewskaanna howthecovid19pandemicchangedtreatmentofsevereaorticstenosisasinglecardiaccenterexperience AT misterskimarcin howthecovid19pandemicchangedtreatmentofsevereaorticstenosisasinglecardiaccenterexperience AT pusleckimateusz howthecovid19pandemicchangedtreatmentofsevereaorticstenosisasinglecardiaccenterexperience AT grygiermarek howthecovid19pandemicchangedtreatmentofsevereaorticstenosisasinglecardiaccenterexperience AT buczkowskipiotr howthecovid19pandemicchangedtreatmentofsevereaorticstenosisasinglecardiaccenterexperience AT lesiakmaciej howthecovid19pandemicchangedtreatmentofsevereaorticstenosisasinglecardiaccenterexperience AT stankowskitomasz howthecovid19pandemicchangedtreatmentofsevereaorticstenosisasinglecardiaccenterexperience AT szarpaklukasz howthecovid19pandemicchangedtreatmentofsevereaorticstenosisasinglecardiaccenterexperience AT ruetzlerkurt howthecovid19pandemicchangedtreatmentofsevereaorticstenosisasinglecardiaccenterexperience AT turanoguz howthecovid19pandemicchangedtreatmentofsevereaorticstenosisasinglecardiaccenterexperience AT jemielitymarek howthecovid19pandemicchangedtreatmentofsevereaorticstenosisasinglecardiaccenterexperience |